Calmark launces a new website

Calmark Sweden AB (publ) launches a new website (www.calmark.se) with an increased focus on products and commercialization. The new website also streamlines internal work with an automatic and integrated translation tool.

The new website will make it easier for potential customers, existing distributors and investors to stay informed about Calmark's products and progress.

"The focus of the new website is sales," says Camilla Arneving, Marketing Director of Calmark. "The website was developed with the goal of being able to quickly expand the number of languages. It lays a foundation for faster and easier reaching out to wide target groups in our focus markets."

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.